7 Tips for Building Analytical Testing that Scales from Development Through Commercial Production

An analytical testing program for drug substance or drug product must evolve throughout development and into commercial production. There is no “set it and forget it” option. The exploratory methods used to characterize an early drug candidate are not designed to support routine commercial batch release. Conversely, going through analytical method development and validation in early R&D is often overkill.

Therefore, manufacturers need an analytical testing program that evolves throughout the product lifecycle — from generating foundational scientific knowledge to generating reproducible, regulatory-ready data and ultimately supporting reliable commercial production.

Key Takeaways

• Analytical testing programs should evolve alongside product development — from early characterization through commercial manufacturing.
• Method development and validation requirements change significantly as products progress toward regulatory submission.
• Designing methods for transferability reduces delays during technology transfer and commercialization.
• Stability studies, supplier qualification, and proactive risk management help ensure long-term product quality.
• Partnering with an experienced analytical testing laboratory can streamline development while supporting regulatory compliance.

Begin by Understanding the Molecule and Its Risks

The early analytical work on a compound establishes the scientific foundation for everything that follows. Before manufacturers can set specifications, select packaging, or design a stability program, they need to confirm the identity of the molecule and understand how it behaves.

Structural elucidation techniques such as nuclear magnetic resonance (NMR), high-resolution mass spectrometry (MS), and Fourier-transform infrared spectroscopy (FT-IR) can confirm molecular identity and reveal important structural characteristics. At the same time, preliminary method development and feasibility studies determine whether the molecule can be measured with sufficient specificity, sensitivity, and consistency.

This early question – whether a  molecule can be accurately and reliably analyzed – can have downstream consequences. A method that cannot adequately separate the API from related compounds or degradation products will not provide a reliable basis for formulation decisions, stability testing, or future quality control.

Forced degradation and stress testing add another layer of understanding. Exposing a compound to heat, humidity, light, oxidation, and different pH conditions help identify likely degradation pathways. The resulting data guide formulation development, reveal whether protective packaging may be necessary, and support the development of analytical methods for measuring stability.

Early testing is therefore less about satisfying a fixed checklist than reducing uncertainty. Each study should help manufacturers understand the product’s risks and prepare for the decisions ahead.

Convert R&D Knowledge into Regulatory-Ready Evidence

As a product advances through development, analytical methods become increasingly standardized and controlled. Early methods may be appropriate for comparing formulations or exploring provisional specification limits without being fully validated. However, methods used to generate data for regulatory submissions must meet much more demanding standards.

Validation in accordance with ICH Q2(R2) establishes documented evidence that an analytical procedure is suitable for its intended purpose. Depending on the procedure, this may include evaluating specificity, accuracy, precision, linearity, range, robustness, and detection or quantitation limits. For oral solid dosage forms, dissolution method development and validation are also important considerations.

Design Analytical Methods for “Transferability”

A method that performs well during development may not perform consistently across different analysts, instruments, or facilities. Transfers often fail because development procedures do not fully document critical details such as sample preparation, column conditioning, or instrument configuration.

Transfer readiness should therefore begin during method development. Procedures should clearly define critical steps, system-suitability requirements, method sensitivities, reference materials, and acceptable instrument parameters. Routine performance monitoring can then identify emerging problems after validation and transfer.

Prepare for Commercial Testing Demands

Development laboratories use analytical methods to explore product behavior and potential specification limits. Commercial quality control laboratories must instead produce timely, reliable results while operating under current Good Manufacturing Practices (cGMP).

For sterile drug products, commercial quality control also includes microbiological testing to confirm that each batch meets applicable safety and quality requirements. Sterility testing assesses whether viable contaminating microorganisms are present, while bacterial endotoxins testing detects lipopolysaccharides that may remain even when viable bacteria are absent. These tests serve different purposes; both are critical for products intended to enter normally sterile areas of the body.

Commercial methods must be validated, robust, and supported by controlled documentation and compliant data systems. Specifications are also refined using development, clinical, stability, registration, and process validation data. Capacity planning becomes critical because staffing shortages, instrument constraints, and investigations into out-of-specification (OOS) or out-of-trend (OOT) results can delay batch disposition.

Protect Testing from Predictable Disruptions

Unavailable reference standards, specialized chromatography columns, or single-source reagents may delay analytical testing. Manufacturers can reduce these risks by proactively monitoring inventory, anticipating lead times, and qualifying backup suppliers where appropriate.

Unexpected impurities create additional challenges. Their identification and characterization may require specialized expertise, advanced instrumentation, and new method development work, potentially affecting batch release, stability conclusions, and regulatory commitments.

Connect Stability with Commercial Performance

Stability testing demonstrates that potency, purity, dissolution, appearance, and other attributes remain acceptable throughout the proposed shelf life. It also informs packaging, storage, distribution, production scheduling, and inventory strategy.

Release testing alone cannot provide this assurance. A batch may meet specifications initially but degrade months later. Ongoing stability programs confirm that commercial-scale manufacturing has not changed the product’s long-term performance.

Select a Partner That Can Support the Product Lifecycle

Many pharmaceutical manufacturers outsource analytical method development and validation to analytical laboratories if they do not have the internal capabilities or bandwidth. Manufacturers should evaluate analytical laboratories based on technical expertise, regulatory history, quality systems, capacity, data reliability, turnaround performance, and communication.

Due diligence should include reviewing recent FDA Form 483 observations, warning letters, and associated CAPAs, particularly those involving data integrity or 21 CFR Part 11 compliance. Audits and performance metrics can provide additional evidence of reliability.

Manufacturers can also submit representative samples for a defined set of tests before transferring full projects, using this trial to directly assess data quality, turnaround, and responsiveness. It is often valuable to obtain practical evidence to complement the documentation-based review.

Strong partners also communicate emerging issues early, explain their potential impact, and recommend practical next steps. By combining scientific expertise with dependable execution and regulatory readiness, the right laboratory can help sustain product quality from early development through commercial supply.

LGM Pharma: Proactive Analytical Testing for Every Stage of Drug Development

LGM Pharma provides analytical testing, including stability services, backed by dedicated project management, highly qualified scientists, and proactive communication from project initiation through completion. By balancing speed with accuracy, continuously monitoring performance, and transparently addressing potential issues, LGM Pharma helps manufacturers keep analytical programs on track without compromising quality.

Contact us today to talk to an analytical testing specialist and learn what partnering with us looks like.

Frequently Asked Questions

1. Why is analytical testing important throughout drug development? Analytical testing generates the data needed to characterize drug substances and drug products, support regulatory submissions, monitor product quality, and ensure consistent commercial manufacturing.
2. When should analytical methods be validated? Analytical methods should be validated before they are used to support regulatory submissions or routine quality control testing. Validation demonstrates that a method is fit for its intended purpose in accordance with applicable regulatory guidelines.
3. What is analytical method transfer? Analytical method transfer is the process of successfully implementing a validated analytical method at another laboratory or manufacturing site while demonstrating equivalent performance.
4. Why is stability testing important? Stability testing demonstrates that a drug product maintains its identity, strength, quality, and purity throughout its intended shelf life under recommended storage conditions.
5. What should manufacturers look for in an analytical testing partner? Manufacturers should evaluate technical expertise, regulatory compliance, quality systems, turnaround times, communication, and the ability to support analytical testing throughout the entire product lifecycle.